



<u>Procedure</u>	<u>Result</u>	<u>Units</u>	<u>Ref Interval</u>	<u>Accession</u>	<u>Collected</u>	<u>Received</u>	<u>Reported/ Verified</u>
Neuronal Antibody (Amphiphysin)	Negative		[Negative]	16-349-900165	14-Dec-16 20:13:00	14-Dec-16 20:13:00	16-Dec-16 14:08:12
Purkinje Cell/Neuronal Nuclear IgG Scrn	None Detected		[None Detected]	16-349-900165	14-Dec-16 20:13:00	14-Dec-16 20:13:00	15-Dec-16 19:13:09
CV2.1 Antibody IgG Screen by IFA	Detected *		[<1:10]	16-349-900165	14-Dec-16 20:13:00	14-Dec-16 20:13:00	15-Dec-16 18:56:41
CV2.1 Antibody IgG Titer by IFA	>1:10240 *		[<1:10]	16-349-900165	14-Dec-16 20:13:00	14-Dec-16 20:13:00	15-Dec-16 18:56:55

14-Dec-16 20:13:00 CV2.1 Antibody IgG Screen by IFA

CV2.1 Antibody, IgG is detected. Titer results to follow. Additional charges apply.

14-Dec-16 20:13:00 Purkinje Cell/Neuronal Nuclear IgG Scrn:

ANNA-1, ANNA-2 or PCA-1 antibodies not detected, confirmatory testing for Hu (ANNA-1), Ri (ANNA-2) or Yo (PCA-1) IgG antibodies will not be performed.

14-Dec-16 20:13:00 Neuronal Antibody (Amphiphysin):
 INTERPRETIVE INFORMATION: Amphiphysin Antibody, IgG

Amphiphysin antibody is present in about 5 percent of patients with stiff-person syndrome and is found variably in other cases of paraneoplastic neurological syndrome (PNS). Amphiphysin antibody is mainly associated with small-cell lung cancer and breast tumors.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

14-Dec-16 20:13:00 Purkinje Cell/Neuronal Nuclear IgG Scrn:
 INTERPRETIVE INFORMATION: Purkinje Cell/Neuronal Nuclear IgG Scrn

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement D: aruplab.com/CS

14-Dec-16 20:13:00 CV2.1 Antibody IgG Screen by IFA:
 INTERPRETIVE INFORMATION: CV2.1 Antibody IgG Screen by IFA

CV2.1 antibodies aid in discriminating between chronic paraneoplastic neurological disorder (PND) and other inflammatory disorders of the nervous system. Anti-CV2.1 is associated with small-cell lung cancer and thymoma.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

14-Dec-16 20:13:00 CV2.1 Antibody IgG Titer by IFA:

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

* Abnormal, # = Corrected, C = Critical, f = Footnote, H = High, L = Low, t = Interpretive Text, @ = Reference Lab